Advances In: Best Practices in RA Management – Applying the Evidence to Optimize Treatment Decision-Making

Released On
November 16, 2020

Expires On
November 16, 2021

Media Type

Completion Time
90 minutes

Rheumatology, Primary Care

Rheumatoid Arthritis

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.

This activity is supported by an educational grant from Sanofi Genzyme.

Credit Available

  • Physicians — maximum of 1.50 AMA PRA Category 1 Credit(s)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This educational activity is directed toward rheumatologists, specialty nurse practitioners, specialty physician assistants, family physicians/primary care physicians, and additional health care providers involved in the treatment and management of patients with RA.

Activity Overview

This online educational activity is designed to provide expert interpretation of new and emerging data on the treatment of rheumatoid arthritis (RA), with a forward-looking perspective on how new and novel agents might impact clinical practice. The essentials of disease diagnosis, current and emerging treatment strategies, and management of treatment-related toxicities will be presented in a multimedia format, including a series of video interviews with expert thought leaders integrated into text-based elements.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Analyze the pathophysiologic underpinnings of rheumatoid arthritis (RA), and understand the importance of early diagnosis as it relates to QoL
  • Review current ACR guidelines regarding RA disease activity measures to guide treatment decisions in patients with RA
  • Evaluate clinical efficacy, safety, and tolerability of current and emerging DMARDs for the treatment of RA
  • Identify shared decision-making strategies for optimizing patient HRQOL with DMARD based therapy


Vibeke Strand, MD, MACR, FACP

Adjunct Clinical Professor
Division of Immunology and Rheumatology
Stanford University School of Medicine
Stanford, CA

Jon T. Giles, MD, MPH

Associate Professor of Medicine
Department of Medicine/Division of Rheumatology
Columbia University Vagelos College of Physicians and Surgeons
New York, NY

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Vibeke Strand, MD, MACR, FACP

  • Consultant: AbbVie, Amgen, Arena Pharmaceuticals, Asana BioSciences, AstraZeneca, Bayer, Bioventus, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Celltrion Healthcare, Corrona, Crescendo Bioscience/Myriad Genetics, EMD Serono, Eupraxia Pharmaceuticals, Flexion Therapeutics, Galapagos, Genentech/Roche, Gilead Sciences, Glenmark Pharmaceuticals, GlaxoSmithKline, Horizon Therapeutics, Inmedix, Janssen, Kezar Life Sciences, Kypha, Lilly, Merck, Novartis, Pfizer, Regeneron Pharmaceuticals, Royalty Pharma, RRD international, Samsung, Samumed, Sandoz, Sanofi, Selecta Biosciences, Servier Laboratories, SetPoint Medical, SKK, UCB.

Jon T. Giles, MD, MPH

  • Grant/Research Support: Pfizer
  • Consultant: Gilead Sciences, Lilly, AbbVie, Bristol Myers Squibb.

The staff of Physicians’ Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Instructions for Participation/How to Receive Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.
You may immediately download your certificate.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.